| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6aaa1a559954102bd42a64bed6dcdd0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2072 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-284
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0065 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 |
| filingDate |
2022-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abb117a2e2b2b00bc9b7c58bbc393415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7faa9cc6fdae668e7884668daa06398d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_205a328044f080c960d98ec6e8bb9153 |
| publicationDate |
2022-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022236288-A1 |
| titleOfInvention |
Gastric residence systems comprising buprenorphine and naloxone |
| abstract |
Provided are gastric residence systems comprising at least one co-extruded drug-eluting component comprising a carrier polymer, buprenorphine or a salt thereof, and naloxone or a salt thereof, and a rate-modulating release fdm coating the at least one co-extruded drug¬ eluting component. The gastric residence systems comprising at least one co-extruded drug¬ eluting component are configured to be maintained within a stomach of a human body for at least 48 hours and to release buprenorphine for at least 48 hours, such that the at least one co¬ extruded drug eluting component with the rate-modulating release film is configured to release at least 10 % of the buprenorphine or the salt thereof after the first 24 hours of residence within the stomach and at least 10 % of the naloxone or the salt thereof after the first 24 hours of residence within the stomach. |
| priorityDate |
2021-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |